IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	)	
	:	Examiner: Unassigned
GILEAD PHARMASSET LLC	)	
	:	Group Art Unit: Unassigned
Divisional of	)	
Application No.: 12/783,680	:	
	)	
Filed: Concurrently Herewith	:	
	)	
For: NUCLEOSIDE	:	
PHOSPHORAMIDATES	)	
	:	January 10, 2013

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PRELIMINARY AMENDMENT

Sir:

Prior to examination on the merits, please amend the application as follows.

Amendments to the Specification:

Please amend the paragraph following the subheading "Priority Claim" and before the subheading "Field of the Invention" on page 1 as follows:

-- ~~The right of priority is claimed to~~This application is a divisional of U.S. Application No. 12/783,680, filed May 20, 2010, which claims priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application Nos. 61/179,923, filed May 20, 2009, and 61/319,513, filed March 31, 2010, all~~the subject matter~~ of which are[[is]] incorporated by reference in their[[its]] entiret[[y]]ies. --

Please amend the sentence on p. 27, lns. 11-12 as follows:

-- In a fourth aspect of the seventh embodiment, the protecting compound is tert-butyl[[-]]dimethyl[[-]]silyl[[-]]_chloride. --

Please amend the first sentence on p. 52, lns. 1-2 as follows:

-- The ratio of two diastereomers S_P:R_P was 9.65[[/]]:1 based on ^{31}P NMR (162 MHz, DMSO-d_6, δ -0.31 (S_P), -0.47 (R_P). --

Please amend the scheme preceding Example 11 on p. 56, lns. 23-24 as follows:



Please amend the scheme for Example 15 on p. 59 as follows:



Amendments to the Claims:

The following listing of the claims replaces all prior versions and listings.

1.-81. (Cancelled).

82. (New): A compound represented by the formula (**4**):



(4)

,

wherein P* represents a chiral phosphorus atom and wherein the compound is at least 97% of the S_P stereoisomer represented by the formula (S_P-**4**):



(S_P-**4**)

,

and not more than 3% of the R_P stereoisomer represented by the formula (R_P-**4**):



(R_P-**4**)

.

83. (New): The compound according to claim 82, wherein the compound is at least 98% of the S_P stereoisomer represented by the formula (S_P-**4**) and not more than 2% of the R_P stereoisomer represented by the formula (R_P-**4**).

84. (New): The compound according to claim 82, wherein the compound is at least 99% of the S_P stereoisomer represented by the formula (S_P-**4**) and not more than 1% of the R_P stereoisomer represented by the formula (R_P-**4**).

85. (New): A pharmaceutical composition comprising the compound according to claim 82 and a pharmaceutically acceptable medium.

86. (New): A pharmaceutical composition comprising the compound according to claim 83 and a pharmaceutically acceptable medium.

87. (New): A pharmaceutical composition comprising the compound according to claim 84 and a pharmaceutically acceptable medium.

88. (New): A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 82.

89. (New): The method according to claim 88 further comprising administering to the human another antiviral agent.

90. (New): A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 83.

91. (New): The method according to claim 90 further comprising administering to the human another antiviral agent.

92. (New): A method of treating a hepatitis C virus infection in a human comprising administering to the human an effective amount of the compound according to claim 84.

93. (New): The method according to claim 92 further comprising administering to the human another antiviral agent.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.